INTROD'UCTION
Osteoarthritis (OA) is the most common arthritic disease. The prevalence of OA increases with age and it may affect as many as 68% Iof patients over the age of 65 (Brandt KD et al., 19'91) . Progressive pain, stiffness, limitation of motion, and deformity of the points characterize the disease. The phamlacological treatment options currently available for OA focus mainly upon the control of pain and inflammation with analgesics and nonIn spite of their proven effectiveness in pain relief and reduction of inflammation, NSAIDs may cause significant adverse effects, including gastrointestinal (GI) toxicity such as gastrit,is and ulcer, as well as renal toxicity @ties JF, 1991; Murray M and Brater D, 1990) . Moreover, NSAIDs do not alter the course of disease progression. A new class of ESAIDs, the selective cycle-oxygenase type-II (COX-II) inhibitors, which were developed in order io reduce GI toxicity, was found tc have clinical efkacy comparable to thg+ nf tmditiirnal NC * 7'7s LA&.&L VI YLUA .l.,Aal^ _ .,.'LLJ- (Lane &E, 1997; Vane JR and Batting -4: 1990) . However, COX-II inhibitors still are only a symptomatic rather than a disease modifying treatment.
Given ::qe high prevalence of &A-alid " 1 :m+d -aA-A____^_d phamiaco I& o,lcal mana,e,,,,,,, vuL 0 m-n+ nntions, much effort has been directed toward developing a more effective and safer drug. In Far East Asian countries, about 600 natural herbs have been used for the treatment of inflammatory 8conditions such as arthritis or lymphad.enitis for many years. Among these 600 herbs of Oriental medicine, 53 species were selected and screened for their analgesic,
anti-mflammatory~ anti-collagenase, and anti-piateier activities in m'L--- Spike (Ahn JS et al.: 1996; Kim HT et aZ.,1996; Park KS et n1.,1995) . The results of preclinical studies demonstrated that SKI306X had significant anti-inflammatory and analgesic properties, improved microcirculation and prevented joint cartilage degeneration in animal models (Choi JH et al., 2002) . A previous double-blind, placebo-controlled
The main objective of this study was to compare the efficacy, safety and tolerability between SKI306X and diclofenac, an NSAID that is one of the leading drugs of its class for the treatment of degenerative joint disease (Amundsen et al., 1983; Todd PA and Sorkin EM, 1998) 
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Following the confirmation of eligibility, patients were randomized to receive either SKI306X 200 mg 3 times daily or diclofenac sustained release (SR) 100 mg once daily.
We used stratified block randomization with stratification by study site using a block using double-dummy technique; 1) assigned code was used strictly throughout the study after randomization, 2) both treatment groups were administered test drugs three times a day using placebo pills. SKI306X group was received SKI306X 200mg and diclofenac 
Assessment of Efjkacy and Sufety
The primary efficacy variable was a change in the visual analogue scale (VAS) from baseline to the fourth week. Pain scores were given by paLXti-IILu UVAAAb . _--_-___-.._~ --G-n+ nc;nrr sa hnG7nntAl 7 (TOmm score instrument labeled with "no pain" at the far left and "worst pain imaginable" on the right (Amndsen T et ii&., L/V&,. "vvI--1 1 oQ?j Qrorps were obtained at baseline, the second week, and the fourth week. Secondary efficacy variables included i) Lequesne index consisting of 11 physician-administered questions about knee pain, walking distance, activities of daily living (Lund 13 et al., 1998) , ii) patients' global satisfaction score using j-point scale (j=completeIy ff t' e ec rve, iC==moderately effective, 3=mildly effective, 2=no change, and 1 =-fi~orse'j, iii) i;l\iestigaioI-s" global s&fa&o~ score usir,g &point scale same as the patients' score based on change of joint effusion, patellar tenderness, joint tenderness, pain on flexion, and active range of motion from baseline tlo 4th week visit.
Spontaneously reported adverse events and vital signs were recorded during each clinic visit Laboratory inv-estigations, including hematology, chemistry, and urinalysis were performed at s'creening and 4th week.
For a!! adversi2 p _ -vents, the investigators assessed causality between the adverse events and decided the degree of causahty as follows: "defiiitely", "possibly and "probabiy" related were scored as "chug-related" adverse events. Causality assessment has been done during the study period before breaking the code of blindness. Patients' compliance was assessed by counting the amount of returned study drugs at the 2nd-and 4th-week visits.
Statrstical Analysis
Efficacy analysis was conducted on the intent-to-treat ( 
. '-I-^o
Change of scores in VAS was computed as end score :minus baseline score, so that positive change scores denote deterioration and negative scores improvement. Paired t-test was used to test the change of V4S score from baseline to the fourth week in each group. After reviewing the relevant literatures on the efficacy trials of NSAIDs, we determined that the pre-defined criterion for non-inferiotity was less than 5mm difference of change in VAS score between two groups (.hrng YB et al., ZOOi). SKI306X wouid be considered clinically not inferior to diclofenac if the lower limit of the 95% confidence inten;al (CI) does not extend beyond the predefined bound of -5 mm on the VAS. The analysis of covariance (AXCOVA) m'odel allowed assessment of the pain score after treatment, as a function of the baseiine p,ain score, treatment group, investigationa! site, sex, and age. The global satisfaction score given by patients and investigators were evaluated using the chi-square test.
The subjects of safety analysis consisted of a population of all treated patients among all randomized subjects. We evaluated the incidence of adverse events during the study and its 9594 confidence intervals, its relationship to drugs and severity of the adverse event.
This study was designed as an equivalence trial with significance level 0.05 and with an 80% power for rejecting non-equivalence if the mean change in 1OOmm VAS scores before and after treatment differed by -5 mm, assuming the standard deviation of change scores within groups was i5.0 mm. Our ciinical experts pane: selected -5 mm nonequivalence criterion based on literatures (Bellamy r\-et al., 1993; Chow SC et al., 1992; Kirchhemer B et al., 1976) and our phase II clinical study (Jung YB et al., 2001 ). This power requirement led to a sample size of 112 per eac'h treatment group Bepar-atzon arzd Composition ofSiU306X SKI306X was prepared from the extracts of three medical herbs, Clematis Radix, Trichosanthes Root and Prunella Spike These extracts were combined at a 1:2: 1 (w/w)
. r ratio with 3C'G (v/v) ethanGi-7qaIer. ~rter tk e;&acted soli$ion -%a~ Filtered and evaporated in vactlo, the residue was partitioned between n-'butanol and water. The nbutanol layer was evaporated in vacua and freeze-dried for complete removal of the residual solvent, yielding the final product in powder form. SKI306X was standardized Reasons for withdrawal were evenly distributed among treatment groups (Table I) [ Table I around here]
Of the 249 patients enrolled, 248 patients were included in the intent-to-treat analysis One patient in diclofenac group was excluded because we found that the patient failed to meet the entry criterion that the patient should have moderate pain greater than 35mm in VAS at the time of entry.
The mean (*SD) change in the Y4S global pain score between the baseline and fourth week visit was -14.18 (117.53) mm in the SKI306X group and -15.49 (*15 37) mm in the UILI"IG~ILzL ,guup. 111b UIILVIUllVC "I SAAWLA^ -*e---D----mp~n rhnnoe btwgen the two _goups was -1 .j i mm with a 95% confidence interval of -4.75 to 2.13 mm (p=O.53, student t-test). The lower one-sided limit of this 95O/b confidence interval did not extend beyond the -5 mm range defined as the non-equivalence criterion, as detailed above in the "Materials and Methods" section.
Further arralysis of the final VAS score was conducted using an analysis of covariance (ANCOVA). The covariates included the baseline pain score, treatment group, investigational site, sex and age. After adjusting for these covariates, there was no significant difference in pain relief between the two groups (p=O.50, ANCOVA test).
The analysis of Lequesne index from baseline to the fourth week indicated that there was c;m;f;rant &ff~~~-e between the two groups (mean&SD): -1.95 (G.77) in SIU306X U'@L"'V""" ..AAI-A-AAdw events (1 S.OO/,)t were rated as severe in the diclofenac group (data not shown). In the diclofenac group one life-threatening serious adverse event of intracranial hemorrhage was reported in a patient with hypertension; however, this event was considered unrelated to the drug by the investigator.
Adverse events most commonly reported in botll groups involved the gastrointestinal system, which accounted for 22.4% of the adverse events in the SKI306X group and 25.8% in the cliclofenac group (Table III) . The majority of clinical adverse events affected _-,^, the &~est+ swtem accounrin~ for 52.5$+32/fii j 3 $_5,6%(2SM4j cf all ,pxr,ts in '93th ---J-----d treatment groups. In special among the digestive system adverse events 'he single most common drug-related clinical adverse event was heartburn, which was observed in 3 patients (4.05%) in SKI306X group and 17 patients (13.7%) in the diclofenac group (~'0.02 1, chi-square test)(data not shown) Table IV shows the result of laboratory measurements, in which the numbers represent the number of patients who had normal laboratory values at baseline and ended with abnormal values at the completion of the study. Elevations of ALT in diclofenac SR were more frequent than that in SKI 306X group (2 vs. 1 I), which was statistically significant difference (p==O.Ol). And also with regard to aspartate aminotransferase (AST), there is more frequent elevation in diclofenac group than in SKI 306X group, although there is no stat&&$! sip&~& ~~iffkpnce fn=O. 10). Regarding vital sims including heart rate and -----------\I-/ blood pressure, there were no clinically or statistically significant changes in time for either treatment.
The effica.cy and safety of SKI306X in treatment of OA of the knee was previously studied in a randomized, double blind, placebo-controlled study (Jung YB et al., 2001 ).
The main goal of this smdy was to compare the efficacy and safety of a SKI306X with diclofenac SR, a NSAID with proven efficacy and safety for the treatment of OA of the knee. The results of this study indicated that the efficacy of SKI306X 200 mg three times a day is comparable to that of diclofenac SR 100 mg a day. Most of all, improvement of primary efficacy variable, VAS, was not significantly different between two groups. This conclusion was supported by the analysis of other secondary efficacy measures such as patients' and investigators' gIoba1 satisfaction assessment score. However, diclofenac did appear to be more efficacious based on the results of the Lequesne index only. In the diclofenac group, there were a greater number of total adverse events than in the SKI306X group, largely due to the greater incidence of increased serum ALT and AST levels in the This study was conducted as a well-designed, randomized, multicenter, double blind study and blmding was mamtained by using double dummy technique, which could reduce the chance of introducing infomration bias on evaiuating the efficacy with highly subjective outcome criteria such as V4S. The Clinicai Trial Center at Seoul National Universiry Hospital has been played a role as a coordinating center for handling all study related problems such as randomization, collecting CRF and standardization of study T..-c.,-oc-c Tn n-J-t +A QCCJJTQ &p c@t\,i cf d&3 -~xcx?o;ernent process2
we used software of ylrvuvL30. L11 "I\.LVI *v YYYUIV .z-------clinical data :management system, ClinTriai 4', which was specifically designed for managing data from clinical trials.
IIowever, the results of primary efficacy variable VAS did not correspond to the results of secondary efficacy variables Lequesne index might be the limitation of this study.
Further study to evaluate this problem will be needed. And, this short treatment is not sufficient to fully reveal the beneficial and adverse (effects of SKI306X, there is a clear need to evaluate SKI306X for a longer treatment period. If the long-term study reveaIs that its efficacy is comparable to that of the other existing NSAIDs and its safety is better than that of the standard NSAIDs therapy, SKI 306X will be regarded as the drug of choice for treating the OA patients.
11-1 i' gp&chij;on tili7is s&;dy ) _^_--showed that SKI306X 2.00 4.1 mg tbn-ee times daiiy has simiiar clinical efficacy, yet superior safety and tolerability, for treating OA of the knee, as compared to dlclofenac SR 100 mg once daily during a four-week treatment period. 2 (57) 1 (29) 11 (314) 7 (20.0) Total number of patients .4E 3, expenencmg 37 (29.6) 43 (34 7) 80 ( 
